Results 61 to 70 of about 10,075 (184)

Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination [PDF]

Vaccines, 2021
Recently several patients, who developed Guillain–Barré syndrome characterized by prominent bifacial weakness after ChAdOx1 nCoV-19 vaccination, were described from different centers. We recently observed a patient who developed a similar syndrome, later in the follow up he showed worsening of the neuropathy two months after the initial presentation ...
Bagella C. F., Corda D. G., Zara P., Elia A. E., Ruiu E., Sechi E., Solla P.   +6 more
openaire   +3 more sources

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens [PDF]

, 2022
Comparative analyses of the immunogenicity and reactogenicity of homologous and heterologous SARS-CoV-2 vaccine-regimens will inform optimized vaccine strategies.
Guckelmus, Candida, Schneitler, Sophie, Klemis, Verena, Schub, David, Marx, Stefanie, Hielscher, Franziska, Sester, Martina, Abu-Omar, Amina, Wagenpfeil, Stefan, Becker, Sören L., Ziegler, Laura, Gärtner, Barbara C., Schmidt, Tina, Sester, Urban, Urschel, Rebecca, Mihm, Janine   +15 more
core   +1 more source

Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines [PDF]

, 2021
Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the ...
Minho Lee (50566), Se Bee Lee (16664046), Dong Keon Yon (3843409), Seung Won Lee (8413776), Lee Smith (59284), Jimin Hwang (9426915), Jae Il Shin (8112179), Ai Koyanagi (430702), Kalthoum Tizaoui (16662249), Louis Jacob (3362735)   +9 more
core   +2 more sources

Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais

Research and Practice in Thrombosis and Haemostasis, 2021
Introduction Vaccine‐induced thrombotic thrombocytopenia (VITT) has been reported after vaccination with the adenoviral vector coronavirus disease 2019 (COVID‐19) vaccine ChAdOx1 nCoV‐19 in European countries.
Phichchapha Noikongdee, Pornnapa Police, Tichayapa Phojanasenee, Pichika Chantrathammachart, Pimjai Niparuck, Teeraya Puavilai, Angsana Phuphuakrat, Pantep Angchaisuksiri, Kochawan Boonyawat   +8 more
doaj   +1 more source

Case report: Early onset Marin-Amat syndrome after receiving ChAdOx1 nCoV-19 vaccination

Frontiers in Medicine, 2022
While vaccination against COVID-19 is still ongoing, some rare adverse events temporally related to vaccinations have been reported, particularly with ChAdOx1 nCoV-19. Here, a 77-year-old male presented to our outpatient department with persistent ptosis
Ping-Feng Tsai, Ping-Feng Tsai, Ping-Feng Tsai, Ying-Jen Chen, Ying-Jen Chen   +4 more
doaj   +1 more source

Vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccine in an older patient: Minireview and a case report

Journal of Infection and Public Health, 2022
Rare cases of unusual thrombosis and thrombocytopenia after administration of the ChAdOx1 nCoV-19 vaccine (AstraZeneca) have been reported. The unusual symptoms are called vaccine-induced immune thrombotic thrombocytopenia (VITT). In the present study, a
Paulo Queiroz Luciano, Renan Binatti, André Rodrigues Sodré, Sérgio Roberto Zajac, Fernando Augusto Lima Marson, Manoela Marques Ortega   +5 more
doaj   +1 more source

Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice

Reproductive Toxicology, 2021
AZD1222 (ChAdOx1 nCoV-19) is a COVID-19 vaccine that is not yet licensed for use during pregnancy. To support the inclusion of pregnant and breastfeeding people in AZD1222 clinical studies, a non-clinical developmental and reproductive toxicity study was performed to evaluate its effects on fertility and reproductive processes of female CD-1 mice ...
Richard Stebbings, Shaun Maguire, Gillian Armour, Christopher Jones, Joanne Goodman, Anna Karin Maguire, Chi Man Tang, Vicky Skellett, Jayne Harris   +8 more
openaire   +2 more sources

Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study

Emerging Microbes and Infections, 2022
Data on real-life vaccine effectiveness (VE), against the delta variant (B.1.617.2) of the severe acute respiratory syndrome coronavirus 2 among various coronavirus disease 2019 (COVID-19) vaccine regimens are urgently needed to impede the COVID-19 ...
Paskorn Sritipsukho, Thana Khawcharoenporn, Boonying Siribumrungwong, Pansachee Damronglerd, Nuntra Suwantarat, Araya Satdhabudha, Chanapai Chaiyakulsil, Phakatip Sinlapamongkolkul, Auchara Tangsathapornpong, Pornumpa Bunjoungmanee, Sira Nanthapisal, Chamnan Tanprasertkul, Naiyana Sritipsukho, Chatchai Mingmalairak, Anucha Apisarnthanarak, Pichaya Tantiyavarong   +15 more
doaj   +1 more source

Additional file 1 of Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19

, 2023
Additional file 1: Table S1. Read codes used for covid-19 vaccination records and diagnosed SARS-CoV-2 infection. Figure S1. A directed acyclic graph of the comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19 and potential
Weiya Zhang (346410), Jeffrey A. Sparks (6041420), Yuqing Zhang (32031), Chao Zeng (452370), Zachary S. Wallace (10217781), Michael Doherty (94933), Na Lu (325317), Jie Wei (264772), Guanghua Lei (8444925), Xiaoxiao Li (195315)   +9 more
core   +1 more source

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults

Human Vaccines & Immunotherapeutics, 2022
We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) and CoronaVac (Sinovac) in healthy adults, as well as booster response to BNT162b2 following
Suvimol Niyomnaitham, Zheng Quan Toh, Patimaporn Wongprompitak, Laddawan Jansarikit, Kanjana Srisutthisamphan, Sompong Sapsutthipas, Yuparat Jantraphakorn, Natthakarn Mingngamsup, Paul V Licciardi, Kulkanya Chokephaibulkit   +9 more
doaj   +1 more source